Is Cochlear becoming a long term play?

COH is navigating a difficult near-term period marked by demand softness, currency headwinds and a material earnings downgrade, but its market leadership, low global penetration rate, Nexa System technology and strong services base make it a credible long-term play for patient investors.

Cochlear Limited (ASX: COH) 

Cochlear Limited  on 22 April 2026 released a trading update and reduced its FY26 underlying net profit guidance to $290 to $330M, down from the previously disclosed range of $435 to $460M. The stock has now fallen 61% year to date in 2026, wiping billions of dollars from its market capitalisation. Market capitalisation at the time of writing is $6.33B. P/E ratio currently stands at 18. Despite the severity of the near-term setback, management has reaffirmed confidence in the company’s long-term growth strategy and its position as the global leader in implantable hearing solutions.

Business updates

Cochlear in its half-year results for the six months ended 31 December 2025 stated. Sales revenue was $1176M, up 1% on the prior corresponding period but down 2% in constant currency. Cochlear implant units grew 6% to 27016, though revenue growth lagged unit growth due to a higher mix of lower-priced emerging market units. Gross margin declined two percentage points to 73%, reflecting the higher proportion of lower-margin emerging market sales and launch costs associated with the new Nucleus Nexa System. Underlying net profit fell 9% to $194.8M while statutory net profit dropped 21% to $161.5M. The company maintained a strong balance sheet with net cash of $173M. The Board declared an interim dividend of $2.15 per share, in line with the prior year and representing a payout ratio of 72% of underlying net profit. decline signalled management’s confidence in the company’s medium-term earnings recovery. Annual yield of the company is at 4.43.

Project Update

The centrepiece of Cochlear’s near-term strategy is the rollout of the Cochlear Nucleus Nexa System, which the company describes as the world’s first and only smart cochlear implant system with upgradeable firmware. The system received FDA approval and was developed over 20 years of research and development. It features internal memory, a Power Compact rechargeable battery delivering the smallest and lightest sound processor with all-day battery life, and intelligent performance that adjusts in real time to changing sound environments. For the first time, recipients can access future innovation through both their implant and sound processor. The Nexa System made up 80% of December implant sales, demonstrating strong initial clinical uptake and surgeon enthusiasm. However, the transition process required new product registrations and contract renewals across developed markets and the contracting process took longer than anticipated, delaying the revenue contribution from the new system in the first half. Management expects the broad availability of the Nexa System to be a key driver of second-half and longer-term revenue growth as the remaining contract renewals are finalised and adoption accelerates across the installed base.

FY26 Outlook

The April 2026 trading update identified five distinct factors driving the earnings downgrade. First, developed market cochlear implant volumes softened materially from January onwards. In the United States, volumes were tracking in line with expectations until mid-February before declining through March, driven by reduced referral activity from the hearing aid channel. In Western Europe, hospital capacity constraints and industrial action in Italy and Spain restricted surgical throughput, producing growing waiting lists in the United Kingdom and Germany. Second, the Middle East conflict introduced commercial disruption, with order cancellations and delivery delays expected in the region and potential receivables provisions of up to $10M net profit impact.

Third, lower production volumes from softer demand compressed gross margin by approximately one percentage point, equating to a roughly $20M net profit impact from lower overhead recoveries. Fourth, Cochlear accelerated its cost base reshaping programme, bringing forward restructuring charges of $18 to $25M above the line in FY26. Fifth, the Australian dollar strengthened from 66 cents to 71 cents against the US dollar and from 56 cents to 61 cents against the euro, generating an approximately $25M after-tax earnings headwind given that Cochlear derives the overwhelming majority of its revenue offshore.

(Source: Company Report)